logo

For the Inventor, By the Inventor

Viby, Denmark

Lene Hjorth Alifrangis

This inventor holds 2 USPTO granted patents, plus 1 CIPO patent and 2 EPO patents. Top assignee: Novo Nordisk A/s. Active years: 2018-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Lene Hjorth Alifrangis. Retrieved from https://idiyas.com/inventor/lene-hjorth-alifrangis

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 2

% Patents Active = 100.0


 

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Location History:

  • Viby, DE (2018)
  • Viby, DK (2020)

Company Filing History:

goldMedal2 out of 1,803 
 
Novo Nordisk A/s
 patents

Years Active: 2018-2020

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents
1. 10815299 - Anti-KIR antibodies, formulations, and uses thereof (2020-10-27),
2. 9879082 - Anti-KIR antibodies, formulations, and uses thereof (2018-01-30),

Title: Lene Hjorth Alifrangis: Innovator in Anti-KIR Antibodies

Introduction

Lene Hjorth Alifrangis is a prominent inventor based in Viby, Denmark. She has made significant contributions to the field of immunology, particularly in the development of anti-KIR antibodies. With a total of 2 patents to her name, her work is paving the way for innovative therapeutic applications.

Latest Patents

Lene's latest patents focus on anti-KIR antibodies, specifically a novel IgG4 isotype anti-KIR antibody. These patents detail formulations and methods for using these antibodies, which are crucial for natural killer (NK) cell activation. The patents also describe compositions, dosages, and administration regimens suitable for therapeutic applications of anti-KIR antibodies. Additionally, they include kits that comprise one or more anti-KIR antibodies with instructions for use in treating cancer.

Career Highlights

Lene Hjorth Alifrangis is currently associated with Novo Nordisk A/S, a leading global healthcare company. Her role at Novo Nordisk allows her to contribute to groundbreaking research and development in the field of biotechnology.

Collaborations

Throughout her career, Lene has collaborated with notable colleagues, including Peter Andreas Nicolai Reumert Wagtmann and Ivan Svendsen. These collaborations have further enhanced her research and innovation in the field.

Conclusion

Lene Hjorth Alifrangis is a trailblazer in the development of anti-KIR antibodies, with her innovative patents contributing significantly to cancer treatment. Her work exemplifies the impact of dedicated research in advancing medical science.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…